Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

NT-I7 (Efineptakin Alfa), en langtidsvirkende human IL-7, Post-Yescarta® (Axicabtagene ciloleucel) eller Post-Breyanzi® (Lisocabtagene maraleucel) hos personer med tilbakefall/refraktisk stor B-celle lymfom

24. september 2026 oppdatert av: Washington University School of Medicine

En fase 1B-studie som evaluerer sikkerhet, toleranse og foreløpig anti-tumoraktivitet av NT-I7 (Efineptakin Alfa), en langtidsvirkende human IL-7, Post-Yescarta® (Axicabtagene colilucel) eller post-breyanzi® (lisocabtagen maraleucel) in-breyanzi® (Lisocabtagen maraleucel) in-cell-cell lisocabtagene maraleucel) in-cell-cell lis med baltystaNeNecel) in-cell-b-cell-cell lisocabtagene maralecel) in-breede (Axicabtagene cellymfoma (Axicabtagene cellymfoma (Axicabtagene cellymfoma (Axicabtagene cellymfoma (Axicabtagene maralecel).

Diffuse large B-cell lymphoma is the most commonly occurring subtype of non-Hodgkin lymphoma, but treatment is often not curative, with as many as 50% of patients with adverse risk factors developing relapsed/refractory disease. CAR T-cell therapy has revolutionized modern cancer therapy, with axicabtagene ciloleucel and lisocabtagene maraleucel (anti-CD19 CAR T-cell therapies) FDA approved for second- or later-line treatment of relapsed/refractory large B-cell lymphoma.

IL-7 plays a crucial role in T-cell homeostasis by inducing thymic differentiation, peripheral expansion, and extrathymic differentiation. It is the main regulator of T-cell hemostasis, inducing T-cell growth and proliferation in lymphopenic patients. There is data that suggests that exposure of T-cells to IL-7 may expand T-cells, prevent T-cell exhaustion, and improve effector functions.

NT-I7 is a long-acting human IL-7 cytokine which has been shown in nonclinical studies to increase peripheral T-cells, antitumor efficacy, and tumor infiltrating lymphocytes, either as a monotherapy or in combination with chemo/radiotherapy and/or immune checkpoint inhibitors and CAR T therapy.

This study is testing the hypothesis that the administration of NT-I7 following standard of care (SOC) approved CD19 CAR T-cell therapies for subjects with relapsed/refractory large B-cell lymphoma (LBCL) will be safe and tolerable and may increase the expansion and persistence of CAR T-cells in vivo, which may result in increased tumor response rate and improved clinical outcomes.

Studieoversikt

Status

Rekruttering

Studietype

Intervensjonell

Registrering (Antatt)

24

Fase

  • Fase 1

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

  • Navn: Zachary D Crees, M.D.
  • Telefonnummer: 314-273-1039
  • E-post: zcrees@wustl.edu

Studiesteder

    • Missouri
      • St Louis, Missouri, Forente stater, 63110
        • Rekruttering
        • Washington University School of Medicine
        • Underetterforsker:
          • John F DiPersio, M.D., Ph.D.
        • Underetterforsker:
          • Feng Gao, Ph.D.
        • Ta kontakt med:
        • Hovedetterforsker:
          • Zachary D Crees, M.D.

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Histologically confirmed relapsed or refractory large B-cell lymphoma, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), high grade B-cell lymphoma, DLBCL arising from an indolent lymphoma, grade 3B follicular lymphoma and primary mediastinal large B-cell lymphoma.

  • Measurable disease by IWG response criteria for lymphoma.

    • Baseline FDG-PET/CT scan must show FDG-avid lesions compatible with CT-defined anatomical tumor sites.
    • A previously irradiated lesion can be considered a target lesion if it is well defined, measurable, and has clearly progressed following radiation.
    • FDG-PET/CT scans done as SOC up to 60 days pre-lymphodepletion therapy will be allowed. NOTE: After eligibility is confirmed, restaging FDG-PET/CT scans will not be used to change eligibility.
  • Eligible for treatment with an FDA-approved SOC CD19 CAR T-cell therapy respective to the current FDA-approved CAR T-cell label for axi-cel(Yescarta®) or liso-cel (Breyanzi®).

  • If the patient has previously received an autologous stem cell transplant, s/he must be at least 3 months post-transplant.

  • At least 18 years of age.

  • ECOG performance status ≤ 2

  • Adequate bone marrow and organ function at the start of lymphodepleting chemotherapy as pre-conditioning for SOC CD19 CAR T-cell infusion as defined below:

    • Absolute neutrophil count ≥ 1.0 K/cumm
    • Platelets ≥ 50 K/cumm
    • Hemoglobin ≥ 8.0 g/dL
    • Total bilirubin ≤ 1.5 x IULN or direct bilirubin ≤ IULN for patients with total bilirubin levels > 1.5 x IULN (except for patients with Gilbert's syndrome, who must have a baseline total bilirubin ≤ 3.0 mg/dL)
    • AST(SGOT)/ALT(SGPT) ≤ 2.5 x IULN (except for patients with documented liver involvement or bone metastases, who must have an AST and/or ALT ≤ 5.0 x IULN)
    • Alkaline phosphatase ≤ 2.5 x IULN (except for patients with liver metastasis, who must have an alkaline phosphatase ≤ 5.0 x IULN)
    • Creatinine clearance ≥ 30 mL/min by Cockcroft-Gault
    • INR and aPTT ≤ 1.5 x IULN unless the patient is receiving anticoagulant therapy and the PT or aPTT is within the therapeutic range for the anticoagulant. Patients who are on anticoagulation should be able to hold the anticoagulant for 4-5 half-lives of the anticoagulant prior to IM NT-I7 injection to reduce risk of hematoma.
  • ECG demonstrating Fridericia's corrected QT interval (QTcF) < 500 ms; patients with QTcF ≥ 500 ms will require clearance by a cardiologist.

  • The effects of NT-I7 on the developing human fetus are unknown. For this reason, women of childbearing potential and men must agree to use adequate contraception prior to study entry, for the duration of study participation, and for 90 days after the last NT-I7 injection. Should a woman become pregnant or suspect she is pregnant while participating in this study or should a man suspect he has fathered a child, s/he must inform her treating physician immediately.

  • Ability to understand and willingness to sign an IRB approved written informed consent document. Legally authorized representatives may sign and give informed consent on behalf of study participants.

Exclusion Criteria:

  • Previous receipt of an allogeneic solid organ transplant or bone marrow transplant.

  • Prior or concurrent malignancy whose natural history has the potential to interfere with the safety or efficacy assessment of the investigational regimen. Patients with prior or concurrent malignancy that does NOT meet that definition are eligible for this trial.

  • Chemotherapy or biologic or hormonal therapy for prior or concurrent cancer treatment, within 14 days prior to the first NT-I7 injection.

    • NOTE: Concurrent use of hormones for non-cancer-related conditions (e.g., insulin for diabetes, hormone replacement therapy) is acceptable.
  • Currently receiving any other investigational agents, or received within 14 days prior to the first NT-I7 injection.

  • Documented active central nervous system (CNS) involvement by lymphoma.

  • A history of allergic reactions attributed to compounds of similar chemical or biologic composition to NT-I7 or other agents used in the study.

  • Presence of clinically significant, unresolved toxicities from prior anticancer therapy, defined as having not received to grade ≤ 1 (with the exception of alopecia and laboratory values listed per the inclusion criteria). Patients with irreversible toxicity that is not reasonably expected to be exacerbated by NT-I7 may be included (e.g., hearing loss, peripheral neuropathy) after consultation with the PI.

  • Uncontrolled intercurrent illness including, but not limited to:

    • Ongoing or active infection (including active hepatitis A or mycobacterium tuberculosis (testing not required))

    • Congestive heart failure with NYHA Class ≥ 2

    • Uncontrolled atrial fibrillation

    • Any of the following within 6 months prior to day of CAR T-cell administration:

      • Unstable angina pectoris
      • Myocardial infarction
      • Coronary artery bypass grafting
      • Coronary angioplasty
      • Coronary stenting
      • Clinically significant cardiac arrhythmia and/or conduction abnormality
    • Other clinically significant cardiac disease that, in the opinion of the treating physician and/or PI, is a contraindication to study treatment

  • History of autoimmune disease for the past 2 years prior to enrollment, including but not limited to: systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjogren's syndrome, Bell's palsy, Guillain-Barre syndrome, multiple sclerosis, vasculitis, or glomerulonephritis.

    • NOTE: The following are exceptions to this criterion: vitiligo, alopecia, type 1 diabetes mellitus, autoimmune hypothyroidism stable on hormone replacement, psoriasis not severe enough to require systemic treatment, diverticulitis not associated with inflammatory bowel disease.
  • Contraindication to intramuscular therapy.

  • Receipt of a live, attenuated vaccine within 30 days prior to NT-I7 injection.

    • NOTE: Patients, if enrolled, should not receive live vaccines during the study period and through 30 days after the last NT-I7 injection. The administration of inactivated vaccines is permitted at any time per the discretion of the treating physician.
  • Pregnant and/or breastfeeding and/or expecting to conceive or father children within the study duration (from enrollment through 90 days after last dose of NT-I7). Women of childbearing potential (including women who have had a tubal ligation) must have a negative serum or urine pregnancy test within 72 hours prior to CAR-T administration. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.

  • HIV-infected if not on effective anti-retroviral therapy with undetectable viral load for 6 months. Patients with HIV who are receiving effective anti-retroviral therapy and have had an undetectable viral load for at least 6 months are eligible.

  • Evidence of chronic hepatitis B virus (HBV) that is detectable on suppressive therapy. Patients with evidence of chronic HBV infection with undetectable HBV viral load on suppressive therapy are eligible.

  • History of hepatitis C virus (HCV) infection that has not been cured or that has a detectable viral load. Patients with a history of HCV that has been treated and cured are eligible. Patients with HCV infection who are currently on treatment and have an undetectable HCV viral load are eligible.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Ikke-randomisert
  • Intervensjonsmodell: Sekvensiell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Eksperimentell: Dose Escalation Dose Level 1 Starting Dose: NT-I7

NT-I7 will be administered as an intramuscular injection at 600 μg/kg on Day 10 (-2/+5 days) and Day 31 (+/-3 days) post-CAR T-cell therapy infusion, with at least 2 weeks between the NT-I7 injections.

Eksperimentell: Dose Escalation Dose Level 2: NT-I7

NT-I7 will be administered as an intramuscular injection at 720 μg/kg on Day 10 (-2/+5 days) and Day 31 (+/-3 days) post-CAR T-cell therapy infusion, with at least 2 weeks between the NT-I7 injections.

Eksperimentell: Dose Expansion (RP2D): NT-I7

NT-I7 will be administered as an intramuscular injection at the recommended phase 2 dose on Day 10 (-2/+5 days) and Day 31 (+/-3 days) post-CAR T-cell therapy infusion, with at least 2 weeks between the NT-I7 injections.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Incidence of adverse events
Tidsramme: From start of CAR T-cell infusion (day 0) through day 90 (post CAR T-cell infusion)

Measured per CTCAE v 5.0. CRS and ICANS will be graded per ASTCT guidelines

From start of CAR T-cell infusion (day 0) through day 90 (post CAR T-cell infusion)
Maximum tolerated dose of NT-I7 (Dose Escalation only)
Tidsramme: From first dose of NT-I7 until 14 days after the second dose NT-I7 dose (estimated to be 35 days)

Determined by incidence and nature of dose-limiting toxicities (DLTs). DLTs are defined in the protocol.

From first dose of NT-I7 until 14 days after the second dose NT-I7 dose (estimated to be 35 days)
Recommended phase 2 dose of NT-I7 (Dose Escalation only)
Tidsramme: Through 90 days after CAR T-cell infusion

Determined by the potential correlation of dose levels with safety and efficacy parameters.

Through 90 days after CAR T-cell infusion

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Effekten av NT-I7 på CAR T-celle ekspansjon målt ved kvantitativ DNA-PCR og/eller flytsytometri
Tidsramme: Fra dag 0 til dag 42 etter CAR T-celle-infusjon
Fra dag 0 til dag 42 etter CAR T-celle-infusjon
Overall response rate (ORR)
Tidsramme: Through completion of follow-up (estimated to be 1 year)

Response will be assessed based on IWG response criteria for lymphoma

Through completion of follow-up (estimated to be 1 year)
Partial response (PR) rate
Tidsramme: Through completion of follow-up (estimated to be 1 year)

Response will be assessed based on IWG response criteria for lymphoma

Through completion of follow-up (estimated to be 1 year)
Complete response (CR) rate
Tidsramme: Through completion of follow-up (estimated to be 1 year)

Response will be assessed based on IWG response criteria for lymphoma

Through completion of follow-up (estimated to be 1 year)
Duration of response (DoR)
Tidsramme: Through completion of follow-up (estimated to be 1 year)

For responders only: defined as the time from the first occurrence of a documented objective response (PR or CR) to the time of the first documented disease progression or death from any cause, whichever occurs first, per IWG.

Response will be assessed based on IWG response criteria for lymphoma

Through completion of follow-up (estimated to be 1 year)
Progression-free survival (PFS)
Tidsramme: Through completion of follow-up (estimated to be 1 year)

Defined as the time from the CAR T-cell infusion (Day 0) to the first occurrence of progression or death from any cause, whichever occurs first, per IWG.

Through completion of follow-up (estimated to be 1 year)
Overall survival (OS)
Tidsramme: Through completion of follow-up (estimated to be 1 year)

Defined as the time from CAR T-cell infusion (Day 0) to death from any cause.

Through completion of follow-up (estimated to be 1 year)

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Zachary D Crees, M.D., Washington University School of Medicine

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

12. mars 2026

Primær fullføring (Antatt)

30. november 2027

Studiet fullført (Antatt)

31. august 2028

Datoer for studieregistrering

Først innsendt

26. juni 2025

Først innsendt som oppfylte QC-kriteriene

26. juni 2025

Først lagt ut (Faktiske)

4. juli 2025

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

29. september 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

24. september 2026

Sist bekreftet

1. september 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

produkt produsert i og eksportert fra USA

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere